Zobrazeno 1 - 10
of 52
pro vyhledávání: '"L O Minushkina"'
Autor:
L O Minushkina
Publikováno v:
Системные гипертензии, Vol 11, Iss 1, Pp 25-29 (2014)
Candesartan is a selective angiotensin II receptor blocker type 1. The distinctive features of its pharmacokinetics and pharmacodynamics are long duration of antihypertensive action, high selectivity and good bioavailability. In the treatment of hype
Externí odkaz:
https://doaj.org/article/306b05c0b581425d90ec1d0a205a44d4
Autor:
L O Minushkina
Publikováno v:
Системные гипертензии, Vol 10, Iss 1, Pp 48-51 (2013)
The paper considers whether b-adrenoblockers may be used in the therapy of hypertension. It views in more detail the specific features of nebivolol, a third-generation highly selective b-adrenoblocker that has properties of acting on endothelial func
Externí odkaz:
https://doaj.org/article/018eb959891840df8826fba44dcf5daf
Autor:
V. A. Brazhnik, L. O. Minushkina, A. D. Erlikh, E. D. Kosmacheva, M. A. Chichkova, N. R. Khasanov, D. A. Zateyshchikov
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 17, Iss 1, Pp 11-15 (2021)
Aim. To study the prognostic value of the ORACLE risk score for assessing the risk of bleeding in patients with acute coronary syndrome (ACS) undergoing anticoagulants for atrial fibrillation using the combined database of the ORACLE II and RECORD 3
Externí odkaz:
https://doaj.org/article/bf38e9ce645d4340af1c0d6ef63657ef
Autor:
V. A. Brazhnik, L. O. Minushkina, A. O. Averkova, E. A. Zubova, N. R. Khasanov, A. S. Galyavich, M. A. Chichkova, E. D. Kosmacheva, D. A. Zateyshchikov
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 19, Iss 5 (2020)
Aim. To compare the diagnostic value of different bleeding risk scales in patients with acute coronary syndrome (ACS).Material and methods. The study included 1502 patients with ACS from the observational, open-label, multicenter trial ORACUL II. The
Externí odkaz:
https://doaj.org/article/5c32b81ba2b147669059b925d0d27d24
Autor:
A. V. Alessenko, M. A. Shupik, U. A. Gutner, D. A. Zateyshchikov, L. O. Minushkina, A. A. Rogozhina, A. T. Lebedev, O. A. Maloshitskaya, S. A. Sokolov, I. N. Kurochkin
Publikováno v:
Journal of Analytical Chemistry. 77:439-449
Autor:
E. D. Kosmacheva, M. A. Chichkova, D. A. Zateyshchikov, V. A. Brazhnik, L O Minushkina, A. D. Erlikh, N. R. Khasanov
Publikováno v:
Racionalʹnaâ Farmakoterapiâ v Kardiologii, Vol 17, Iss 1, Pp 11-15 (2021)
Aim. To study the prognostic value of the ORACLE risk score for assessing the risk of bleeding in patients with acute coronary syndrome (ACS) undergoing anticoagulants for atrial fibrillation using the combined database of the ORACLE II and RECORD 3
Autor:
L. O. Minushkina
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 12, Iss 5, Pp 75-80 (2013)
This review presents the evidence on the benefits of fixed-dose combination therapy for arterial hypertension management. The focus is on the combination of a third-generation dihydropyridine calcium antagonist lercanidipine and an ACE inhibitor enal
Externí odkaz:
https://doaj.org/article/0205df1442c3455abbcb6e3db9f079e6
Autor:
V. A. Brazhnik, A. S. Galyavich, Tereshchenko Sn, M G Glezer, E. D. Kosmacheva, D. A. Zateyshchikov, M. A. Chichkova, N. R. Khasanov, N. A. Koziolova, V. O. Konstantinov, Boeva Oi, L. O. Minushkina, Khorolets Ev
Publikováno v:
Kardiologiia. 60:30-37
Aim To analyze results of changing the management tactics in patients with acute coronary syndrome (ACS) in clinical practice from 2004 through 2018 expressed as improvement in prognosis.Material and methods Results of two observational studies were
Autor:
M. A. Shupik, U A Gutner, S A Sokolov, A. V. Alessenko, L O Minushkina, Olga A. Maloshitskaya, I N Kurochkin, D A Zateyshchikov, A A Rogozhina
Publikováno v:
Bulletin of Russian State Medical University. :84-91
Development of modern methods for metabolome assessment, such as gas chromatography–mass spectrometry, allows one to expand the knowledge about the features of lipid metabolism in various clinical conditions. The study was aimed to investigate lipi
Autor:
U A Gutner, IN Kurochkin, D A Zateyshchikov, A A Rogozhina, L O Minushkina, Olga A. Maloshitskaya, A. V. Alessenko, MA Shupik, Albert T. Lebedev
Publikováno v:
Bulletin of Russian State Medical University.
Lipid-lowering drugs affect standard lipoproteins. However, we have no knowledge of changes in other plasma lipids upon treatment. The study was aimed to assess the dynamic changes in cholesterol, high- and low-density lipoproteins (HDL and LDL), tri